AuntMinnie
MARCH 26, 2024
Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
AuntMinnie
DECEMBER 19, 2023
“The results obtained with a portable PET scanner in this comparison in humans require follow-up but lend confidence to the feasibility of more flexible and portable brain imaging with PET,” noted first author Elizabeth Bartlett, PhD, of the New York State Psychiatric Institute. In 2018, the group received a grant from the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JUNE 20, 2024
Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
Imaging Technology
MAY 31, 2023
Flavio Forrer , MD, PhD, Chairman of Nuclear Medicine in the Division of Radiology and Nuclear Medicine at Kantonsspital St. Measurement follows NEMA NU 2-2018. [v] v] Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing. [vi]
Imaging Technology
JUNE 15, 2023
For pharmaceutical companies and researchers, using this tracer to better understand the mechanism of action - i.e. the effect of immunotherapies on a patient’s immune response to their cancer - could, potentially, enable them to better select patients to participate in clinical trials and bring new immunotherapies to market. Fruhwirth, G.
Expert insights. Personalized for you.
122 
Let's personalize your content